Highlights of the important and interesting in the world of healthcare:
Novartis to pay for Gilenya. Novartis will pay out-of-pocket costs for patients who use its new multiple sclerosis drug Gilenya — up to $800 a month. And the drugmaker will foot the bill — up to $600 — for clinical testing and monitoring the FDA required as part of the product’s approval, according to FiercePharma.
Middlemen waste billions. Hospitals and health providers that purchase medical devices through group purchasing organizations waste billions of dollars each year, according to a new study funded by the Medical Device Manufacturers Association, according to Kaiser Health News.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pharma expected to grow more in 2011. The value of the global pharmaceutical market is expected to grow between 5 percent and 7 percent next year, reaching $880 billion, up from the 4 percent-to-5 percent growth that’s expected this year, according to a new report from IMS Health, Pharmalot blog reports.
Healthcare social media mistakes. Whether you are in private practice or work for a group of large hospital networks, social media mistakes can be costly in terms of misrepresenting your specialty, breaching patient confidentiality or limiting your business growth, writes blog KevinMD.com.
Healthcare innovation? Not much. Only 10 percent of healthcare services firms reported a process innovation from 2006 to 2008, according to a National Science Foundation report on innovation cited by Washington Posts blogger Ezra Klein.
